Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
In a regulatory filing Friday, Agenus Inc (NASDAQ:AGEN) revealed Bristol Myers Squibb & Co (NYSE:BMY) terminated a license, development, and commercialization agreement forged in 2021.
The company said that as part of a broader strategic realignment of their development pipeline, which involves other licensed products, Bristol Myers Squibb is returning AGEN1777, a TIGIT bispecific antibody, to Agenus and voluntarily terminating the BMS License Agreement, effective as of January 26, 2025.
Related: Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity.
Most recently, Roche Holdings AG's (OTC:RHHBY) TIGIT drug, tiragolumab, failed in Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC) and did not meet its co-primary endpoint of progression-free survival.
In August last year, Roche was made aware of the inadvertent disclosure of the second interim analysis of the Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus Tecentriq (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for PD-L1-high locally advanced or metastatic non-small cell lung cancer.
In May, Merck & Co Inc (NYSE:MRK) discontinued the vibostolimab, its TIGIT drug, and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial.
Results from Merck's Phase 2 KeyVibe-002 trial of vibostolimab/pembrolizumab combo, with or without docetaxel for metastatic non-small cell lung cancer with progressive disease after treatment with immunotherapy and platinum-doublet chemotherapy, did not show an improvement in median PFS compared to docetaxel alone.
Bristol Myers acquired AGEN1777 in 2021 by paying Agenus $200 million in cash.
Price Action: AGEN stock is down 7.10% at $5.23 at last check Monday.
Read Next:
Don't miss the opportunity to dominate in a volatile market at the Benzinga SmallCAP Conference on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you're a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!
"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!
Get the latest stock analysis from Benzinga?
This article Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
